Mice carrying a targeted disruption of the Npr1 gene (coding for guanylyl cyclase/natriuretic peptide receptor A (NPRA)) exhibit increased blood pressure, cardiac hypertrophy, and congestive heart failure, similar to untreated human hypertensive patients. The objective of this study was to determine whether permanent ablation of NPRA signaling in mice alters the expression of matrix metalloproteinase (MMP)-2 and MMP-9 and proinflammatory mediators such as tumor necrosis factor-␣ (TNF-␣), leading to myocardial collagen remodeling. Here, we report that expression levels of the MMP-2 and MMP-9 genes were increased by 3-5-fold and that the expression of the TNF-␣ gene was enhanced by 8-fold in Npr1 homozygous null mutant (Npr1 ؊/؊ ) mouse hearts compared with wild-type (Npr1 ؉/؉ ) control mouse hearts. Myocardial fibrosis, total collagen, and the collagen type I/III ratio (p < 0.01) were dramatically increased in adult Npr1 ؊/؊ mice compared with agematched wild-type counterparts. Hypertrophic marker genes, including the -myosin heavy chain and transforming growth factor-1, were significantly up-regulated (3-5-fold) in both young and adult Npr1 ؊/؊ mouse hearts. NF-B binding activity in ventricular tissues was enhanced by 4-fold with increased translocation of the p65 subunit from the cytoplasmic to nuclear fraction in Npr1 ؊/؊ mice. Our results show that reduced NPRA signaling activates MMP, transforming growth factor-1, and TNF-␣ expression in Npr1 ؊/؊ mouse hearts. The findings of this study demonstrate that disruption of NPRA/cGMP signaling promotes hypertrophic growth and extracellular matrix remodeling, leading to the development of cardiac hypertrophy, myocardial fibrosis, and congestive heart failure.
Atrial (ANP)1 and brain (BNP) natriuretic peptides elicit natriuretic, diuretic, vasorelaxant, and anti-proliferative responses, all of which contribute to the regulation of blood pressure and blood volume homeostasis (1, 2). ANP and BNP bind to guanylyl cyclase/natriuretic peptide receptor A (NPRA), which is considered a major natriuretic peptide receptor that synthesizes the intracellular second messenger cGMP (3). Mice carrying a targeted disruption of the Npr1 gene (encoding NPRA) exhibit hypertension, marked cardiac hypertrophy, and congestive heart failure, with sudden death after 6 months of age (4 -6). On the other hand, Npr1 gene-duplicated mice have stimulated levels of guanylyl cyclase activity and increased accumulation of intracellular cGMP in a gene dose-dependent manner and exhibit protection against high salt diets (7). In vitro studies have shown that the ANP/NPRA system exerts growth inhibitory effects on hypertrophic agonist-induced proliferation of cardiac myocytes (8, 9), fibroblasts (10), and mesangial and human vascular smooth muscle cells (11,12). Furthermore, transgenic mice overexpressing ANP have smaller hearts compared with wild-type mice, and ANP gene delivery attenuates cardiac hypertrophy in spontaneously hypertensive rats (13). Nonetheless, the molecular mechanism by which the...